A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
NCT07704866
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Claudin 18.2
Solid Tumor Malignancies
Interventions
DRUG:
FG-B901
DRUG:
FG-B901
DRUG:
FG-M108
Sponsor
FutureGen Biopharmaceutical (Beijing) Co., Ltd